For Research Use Only. Not for use in diagnostic procedures.

Monoclonal

IgG2a/K

Mouse

Cytokeratin 17 is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.

Store at 2 to 8 degree C in the dark.

Manufactured in an ISO 13485:2016 Certified Laboratory.

Small volumes of anti-KRT17 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Cytokeratin 17 (CK 17) is a Type I cytokeratin with a MW of 46 kD found sometimes in association with Cytokeratin 7. Cytokeratin 17 is found in nail beds, hair follicles, sebaceous glands, and other epidermal appendages. Mutations in the gene encoding this protein lead to Jackson-Lawler type Pachyonychia Congenita and Steatocystoma Multiplex.Cytokeratin 17 antibody has been used to distinguish immature Cervical Squamous Metaplasia from High Grade Cervical Intraepithelial Neoplasia (CIN III). Anti-CK 17 also labels myoepithelial cells in the benign breast tissue. CK 17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK 5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK 17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK 17. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK 17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

Immunohistochemistry (IHC) Formalin/Paraffin

IHC of CK 17 on an FFPE Cervical Cancer Tissue

48,106 Da[Similar Products]

keratin 17

keratin, type I cytoskeletal 17

Keratin, type I cytoskeletal 17

CK-17; K17??[Similar Products]

K1C17_HUMAN

This gene encodes the type I intermediate filament chain keratin 17, expressed in nail bed, hair follicle, sebaceous glands, and other epidermal appendages. Mutations in this gene lead to Jackson-Lawler type pachyonychia congenita and steatocystoma multiplex. [provided by RefSeq, Aug 2008]

K17: a type I cytoskeletal keratin. The keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells and are subdivided into cytokeratins and hair keratins. There are two types of cytoskeletal and microfibrillar keratin: type I (acidic; 40-55 kDa) [K9 to K20] and type II (neutral to basic; 56-70 kDa) [K1 to K8]. Both a basic and an acidic keratin are required for filament assembly. Generally associates with K6.

Protein type: Cytoskeletal

Chromosomal Location of Human Ortholog: 17q21.2

Cellular Component: cytoplasm; intermediate filament

Molecular Function: MHC class II protein binding; MHC class II receptor activity; protein binding; structural constituent of cytoskeleton

Biological Process: epidermis development; hair follicle morphogenesis; intermediate filament organization; keratinization; positive regulation of cell growth; positive regulation of hair follicle development; positive regulation of translation; signal transduction

Disease: Pachyonychia Congenita 2; Steatocystoma Multiplex

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.